Patent SG-11201810159T-A (SG)
Title: Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
Inventor: ENDELL JAN
IPC: G01N33/574
Filed: 2017-05-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIP0 I PCT 0111111010 0111 inn III VIII ioo lID IIII HID oimIE (10) International Publication Number WO 2017/207574 Al (51) International Patent Classification: GO1N 33/574 (2006.01) (21) International Application Number: PCT/EP2017/063045 (22) International Filing Date: 30 May 2017 (30.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16171885.3 30 May 2016 (30.05.2016) EP (71) Applicant: MORPHOSYS AG [DE/DE]; Semmelweis- strasse 7, 82152 Martinsried/Planegg (DE). (72) Inventors: ENDELL, Jan; Barer Str. 36, 80333 Miinchen (DE). WINDERLICH, Mark; Implerstr. 52, 81371 Miinchen (DE). BOXHAMMER, Rainer; Egmatinger Str.5, 85653 Aying (DE). (74) Agent: SPIELER, Stephan; Semmelweisstr. 7, 82152 Planegg (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS • (57) : The present disclosure is directed to a method of identifying a subject having chronic lymphocytic leukemia (CLL), 7r non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL) or acute lymphoblastic leukemia (ALL) that is responsive to I N • treatment with an anti-CD19 antibody, said method comprising: a) providing a blood sample obtained from said subject prior to treatment N with said anti-CD19 antibody, b) determining the level of at least one biomarker in said sample selected from the group consisting of: i) 0 peripheral NK cell count, and ii) CD16 expression levels on peripheral NK cells, c) comparing the level of said at least one biomarker in \" said sample to a predetermined cut off level, wherein levels of said at least one biomarker at or above the predetermined cut off level is • indicative of a subject who would benefit from treatment with an anti-CD19 antibody. The present disclosure is also directed to a method C for selecting a patient for treatment according to the above and to the use of an anti-CD19 antibody for the treatment of such a patient.